Integrated Pharmaceutical Care on Patients with Coronary Heart Diseaseafter First Percutaneous Coronary Intervention
XU Nong-zhang1,2, LI Zhong-dong1*
1. Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai 200040,China; 2. Department of Pharmacy, Zhoupu Hospital of Shanghai Pudong New District, Shanghai 201318, China
ժҪĿ�� ̽��ȫ�̻�ҩѧ����Թ��IJ������״ξ�Ƥ��״����������(PCI)�����ҩ�����ԡ�Σ�����ؿ��ơ����꼰2��Ԥ���Ӱ�졣���� �ռ�2015��1��~12�����Ϻ�����ҽѧԺ��������ҽԺ��ȷ���Ϊ���IJ����״γɹ���PCI���Ļ���200 ��,�����Ϊ�������ҩʦ��Ԥ��,ÿ�� 100������������г������ƺͻ���;ҩʦ��Ԥ���ڴ˻�����,��ҩʦ����ҩѧ��Ԥ(�����Ż�ҩ�����Ʒ������ƶ�ҩѧ��ƻ�����ҩ�������������̼�����ҩʦ�������),2����������2�ꡣ�ֱ�Ƚϰ�����2���2����סԺ�ʡ���Ҫ���������¼�(MACEs)�����ʡ���סԺ���á����IJ����ö���Ԥ��ҩ��֪���ʡ���ҩ�����Լ������������;�Ƚ�2�������Σ�����ؿ����������� �����,ҩʦ��Ԥ����סԺ�ʡ�MACEs�����ʼ���סԺ���þ����ڶ�����,��ҩ�����Խ϶������Ը�(94.9% vs. 87.4%);2���,ҩʦ��Ԥ��Σ�����ؿ��ƴ�����������ڶ�����(����:3.1% vs. 12.6%,P=0.012;Ѫ�Ǵ����:79.6% vs. 62.1%,P=0.007;Ѫѹ�����:74.5% vs. 53.7%,P=0.003;Ѫ֬�����:84.7% vs. 57.9%,P<0.001),���ö���Ԥ��ҩ����֪�ʡ�����������Լ���ҩ�������������ڶ�����(P<0.001),2����סԺ�ʡ�MACEs�������Լ���סԺ���þ����Ե��ڶ����顣���� ҩʦ��PCI�����߽�������ҩѧ��Ԥ����Ч����ߵķ�ҩ������,��������Σ�����غ�MACEs������,����ҽ�Ʒ���,�������ٴ�Ԥ��;����Щ��ԤЧ�������ʱ��ϳ�ʱ��������
Abstract��OBJECTIVE To explore the effect of integrated pharmaceutical intervention on medication compliance, risk factors control, and 6 months and 2 years prognosis in patients with coronary artery disease(CAD) after first percutaneous coronary intervention (PCI) in china. METHODS 200 cases of patients diagnosed with CAD and underwent PCI successfully firstly in Zhoupu hospital during January 2015 to December were enrolled. The control group was given routine treatment and nursing care; pharmacist intervention group, on this basis, was given pharmaceutical intervention by pharmacists, including optimizing medication program, formulating pharmaceutical care plan, medication education, health education and regular pharmacists outpatient follow-up. The two groups were followed up for two years. Comparison of the Readmission(Readm) rate, incidence rate of major adverse cardiac events (MACEs), Readm expenses, awareness rate of commonly used two-grade preventive drugs for CAD, medication compliance and emotion management after 6 months and two years in the two groups. The control of risk factors in the two groups after 2 years were compared. RESULTS After six months, the Readm rate, the incidence of MACEs and Readm expenses in pharmacist intervention group were lower than those in the control group, and the medication compliance was slightly higher than the control group (94.9% vs 87.4%); two years later, the standard rate of risk factors in pharmacist intervention group was significantly better than the control group(smoking3.1% vs. 12.6%, P=0.012; blood glucose standard rate79.6% vs. 62.1%, P=0.007; blood pressure standard rate74.5% vs. 53.7%, P=0.003; blood lipid standard rate84.7% vs. 57.9%, P<0.001); and the Readm rate, the incidence of MACEs and the cost of Readm were significantly lower than those of the control group after six months and two years . CONCLUSION Pharmacists�� active pharmaceutical intervention on patients after PCI can effectively improve the medication compliance of the patients, reduce the postoperative risk factors and the incidence of MACEs, reduce medical expenses, improve the clinical prognosis, which were more significant when the follow-up time was longer.
��Ū��, ���ж�. ȫ�̻�ҩѧ����Թ��IJ������״�PCI����Ԥ���Ӱ��[J]. �й�ҩѧ��־, 2019, 54(10): 823-827.
XU Nong-zhang, LI Zhong-dong. Integrated Pharmaceutical Care on Patients with Coronary Heart Diseaseafter First Percutaneous Coronary Intervention. Chinese Pharmaceutical Journal, 2019, 54(10): 823-827.
CAO Y, YAO L, FANG F. Analysis of related risk factors influence the development speed of coronary lesions in myocardial infarction patients after PCI operation. Mod J Integr Tradit Chin West Med(�ִ�����ҽ�����־), 2015,24(25):39-42.
[2]
HO P M, MAGID D J, SHETTERLY S M, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Americ Heart J, 2008, 155(4):772-779.
[3]
YUSUF S, ISLAM S, CHOW C K, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet, 2011, 378(9798):1231-1243.
[4]
HILLIS L D, SMITH P K, ANDERSON J L, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary:a report of the American College of Cardiology Foundation/American Heart Assocication Task Force on Practice Guidelines. J Thorac Cardiovasc Surg, 2012,143(1):4-34.
[5]
JONES K, SAXON L, CUNNINGHAM W, et al. Secondary prevention for patients after a myocardial infarction: summary of updated NICE guidance. BMJ, 2013, 47(3):f6544.
[6]
EXPERT COMMITTEE ON RATIONAL DRUG USE OF NATIONAL HEALTH AND FAMILY PLANNING COMMISSION, CHINESE PHARMACISTS ASSOCIATION. Guidelines on rational drug use for coronary heart disease. Chin J Front Med Sci(Elect Ver)(�й�ҽѧǰ����־���Ӱ�), 2016, 8(6):19-108.
[7]
CORDERO A, RODRIGUEZ PADIAL L, BATALLA A, et al. Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain. Results from the CAPS study. Cardiovasc Ther, 2016, 35(2). doi: 10.111,1/1,755-5922.12240.
[8]
SANTSCHI V, CHIOLERO A, BURNAND B, et al. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and Meta-analysis of randomized trials. Arch Intern Med, 2011, 171(16):1441-1453.
[9]
CAI H, DAI H, HU Y, et al. Pharmacist care and the management of coronary heart disease: a systematic review of randomized controlled trials. BMC Health Serv Res, 2013, 13(1):1-7.
[10]
TANG F M, WANG B. Brief analysis on status quo of domestic and foreign medication education for patients. J China Pharm(�й�ҩ��),2013(13):1245-1248.
[11]
WRITING GROUPOF CHINESE GUIDELINES FOR THE MANAGEMENT OF HYPERTENSION. 2010 Chinese guidelinesfor the management of hypertension. Chin J Cardiol(�л���Ѫ�ܲ���־),2011, 39(7): 579-615.
[12]
AMERICAN DIABETES ASSOCIATION.Standards of medicalcare in diabetes-2012. Diabetes Care, 2012, 35(suppl 1): s11-s63.
[13]
JOINT COMMITTEE ON THE ESTABLISHMENT OF GUIDELINES FOR THE PREVENTION AND TREATMENT OF DYSLIPIDEMIA IN CHINESE ADULTS(2007). Chinese guidelineson prevention and treatment of dyslipidemia in adults. Chin J Cardiol(�л���Ѫ�ܲ���־),2007,35(5):390-419.
[14]
SWIECZKOWSKI D, MOGIELNICKI M, CWALINA N, et al. Medication adherence in patients after percutaneous coronary intervention due to acute myocardial infarction: from research to clinical implications. Cardiol J, 2016, 23(5):483-490.
[15]
FARKOUH M E, BODEN W E, BITTNER V, et al. Risk factor control for coronary artery disease secondary preventionin large randomized trials. J Am Coll Cardiol, 2013,61(15):1607-1615.
[16]
CLARK A M, HARTLING L, VANDERMEER B, et al. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med, 2005, 143(9): 659-672.
[17]
ZHAO S, ZHAO H, WANG L, et al. Education is critical for medication adherence in patients with coronary heart disease. Acta Cardiol, 2015, 70(2):197-204.
[18]
ZHANG X J, YANG M.The effect of medication reconciliation in patients withmedication errors in cardiology department. Chin Pharm J(�й�ҩѧ��־), 2013,48(3):234-237.
[19]
LIANG Y, YANG H M, HAN J, et al. Clinical pharmacist participation in chronic disease management in risk survey of coronary heart disease patients. Chin J Hosp Pharm(�й�ҽԺҩѧ��־),2015, 35(19):1778-1782.
[20]
MICHAL M, SIMON P, GORI T, et al. Psychodynamic motivation and training program (PMT) for thesecondary prevention in patients with stable coronary heart disease:study protocol for a randomized controlled trial of feasibility andeffects. Trials, 2013, 14:314.
[21]
KOVACS A H, MOONS P. Psychosocial functioning and quality of life inadults with congenital heart disease and heart failure. Heart Fail Clin, 2014, 10(1):35-42.
[22]
ZHAO S J, ZHAO H W, DU S, et al. The impact of clinical pharmacist support on patients receiving multi-drug therapy for coronary heart disease in China. Indian J Pharm Sci, 2015, 77(3):306-311.
[23]
ZHOU S Y, WANG Y M, WANG Z J, et al. Effects of pharmaceutical intervention after discharge on medication compliance and the prognosis of coronary artery diseases patients after PCI in primary hospital. J China Pharm(�й�ҩ��),2017, 28(8):1126-1129.
[24]
HONG M H, XU D X, TONG S M, et al. Investigation and analysis of medication adherence and influencing factors among acute myocardial Infarction patients with coronary stent implantation . Chin Nurs Manag(��������),2014, 14(12):1261-1265.
2019, Vol. 54 
